Best Grants for Cancer Nonprofits in American Samoa

The Research Scholar Grants (RSG) by the American Cancer Society support independent researchers engaged in cancer-related studies. Eligible applicants must be affiliated with US academic institutions and have been appointed as independent faculty for less than ten years. Grants provide funding up to $215,000 annually for direct costs and allow for 10% indirect costs, with project durations of up to four years, fostering innovative cancer research across various priority areas.

The National Cancer Institute (NCI) is set to release a Notice of Funding Opportunity (NOFO) aimed at advancing informatics technologies for cancer research. This initiative will support the development of tools that enhance data acquisition, management, and analysis throughout the cancer continuum. By focusing on technologies with proven impact, the NOFO seeks to optimize and sustain resources critical for cancer biology, diagnosis, treatment, and epidemiology.

The National Cancer Institute (NCI) invites applications for transformative research in cancer biology and oncology through nanotechnology. This funding opportunity aims to address significant challenges by exploring the interactions of nanomaterials with biological systems. Projects should focus on utilizing nanoparticles and devices for targeted cancer therapies and enhancing diagnostic capabilities. Successful proposals will contribute to the foundational knowledge necessary for future nanotechnology-based interventions in cancer treatment.

The Discovery Boost Grants (DBG) offered by the American Cancer Society support innovative and high-risk exploratory cancer research. These grants, available for up to two years with a funding limit of $125,000 annually plus indirect costs, aim to generate preliminary data that can lead to further funding opportunities. Eligible applicants include independent investigators with a doctorate and a full-time faculty position, fostering advancements in cancer research across multiple priority areas.

The Mission Boost Grants (MBG) by the American Cancer Society aim to enhance cancer research by funding projects that translate into human testing. These grants support investigators at all levels, offering resources for innovative clinical projects. The program consists of two funding stages: Stage I focuses on developing clear milestones for new treatments, while Stage II supports patient testing, ultimately contributing to advancements in cancer care and treatment.

The Goldberg-Reeder Resident Travel Grant, awarded by the American College of Radiology, supports radiology and radiation oncology residents and fellows in their international volunteer efforts. Each year, qualified applicants can receive funding to spend a minimum of one month providing healthcare services in developing countries. This initiative encourages trainees to gain valuable experience while addressing healthcare needs in underserved areas, thereby enhancing their professional growth and contributing positively to global health.

The American Cancer Society's Mentored Research Grants for Postdoctoral Fellowships (PF) aim to support emerging researchers in their training programs, fostering their transition to independent cancer research careers. Eligible candidates include US citizens or non-citizens with valid visas who have completed their doctoral degrees within the last four years. The fellowship offers funding for up to three years, with stipends of $66,000 to $70,000 annually, alongside allowances for health insurance and professional development.

The FY26 Peer Reviewed Cancer Research Program's Idea Award promotes innovative, high-risk cancer research initiatives. It supports groundbreaking concepts that advance cancer knowledge, patient care, and treatment options within the Military Health System. Projects must demonstrate creativity and innovation, avoiding incremental advancements. Notably, the Early Career Investigator Option is available to foster the growth of promising new investigators early in their careers. This award aims to make significant contributions to cancer research for Service Members and Veterans.

The Clinician Scientist Development Grant (CSDG) by the American Cancer Society supports full-time faculty aiming to become independent clinician scientists while maintaining clinical practice. Eligible applicants must hold a doctoral degree, an active clinical license, and have clinical care experience. The grant provides funding of $135,000 annually for 3 to 5 years, including allowable indirect costs, to advance cancer research in key priority areas.

The DoW Peer Reviewed Cancer Clinical Trial Award supports the rapid initiation of clinical trials aimed at significantly improving cancer treatment. Projects may range from small pilot studies to large-scale phase III trials, focusing on innovative products, drugs, or devices. This award mandates the inclusion of patient advocates and prohibits animal studies, ensuring that all preclinical work is completed prior to the award start date. Regulatory applications must be submitted if required for the proposed trials.

The FY26 Peer Reviewed Cancer Research Program Impact Award promotes significant research aimed at enhancing clinical cancer care. It requires preliminary data to ensure feasibility and emphasizes projects with a strong potential for immediate impact. This funding supports clinical trials and allows for either a single Principal Investigator or a duo of partnering PIs, ensuring that both can contribute distinct aspects of the research. Applications must be carefully coordinated to avoid withdrawal risks.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The Cancer-Related Behavioral Health Fund, established by the HealthWell Foundation, provides financial assistance to individuals diagnosed with cancer for behavioral health treatments. This fund covers costs associated with prescription drugs, counseling services, and transportation. Aiming to alleviate financial burdens, it ensures that underinsured patients can access necessary care without delay. In 2024, the foundation awarded over $1.2 billion, emphasizing its commitment to improving health outcomes for cancer patients across the United States.

The Chronic Lymphocytic Leukemia Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients battling chronic lymphocytic leukemia (CLL). This fund provides essential support for prescription copays and premiums, ensuring that patients can access necessary treatments without the stress of financial constraints. Since its inception, the foundation has awarded over $1.2 billion in grants, helping more than 1.1 million patients. The initiative emphasizes the importance of accessible healthcare and aims to improve the quality of life for those affected by this condition.

The Mantle Cell Lymphoma Fund, managed by the HealthWell Foundation, provides financial assistance to underinsured patients diagnosed with Mantle Cell Lymphoma. The fund covers prescription drug copays and Medicare Part B premiums, with a maximum award of $8,500. Eligible patients must have insurance that covers their medication and meet specific income guidelines. The foundation aims to reduce financial barriers to essential treatments, ensuring that patients receive necessary care without undue financial strain.

The ACS - Fanconi Cancer Foundation Discovery Boost Grant invites innovative proposals for translational cancer research addressing the challenges faced by individuals with Fanconi anemia (FA). This grant supports high-risk, high-reward projects aimed at improving detection, prevention, or treatment of FA-related cancers. With funding of up to $135,000 per year for two years, it encourages research in early detection technologies, prevention mechanisms, and therapeutic strategies tailored to the unique sensitivities of the FA population.

The Amyloidosis Fund, managed by the HealthWell Foundation, provides essential financial assistance to underinsured patients facing treatment costs for Amyloidosis. The program covers prescription copays, insurance premiums, and related expenses, ensuring that patients can access necessary medications without financial strain. With a maximum award of $8,000, the fund aims to alleviate the burden of healthcare costs for those diagnosed with this complex disease, promoting better health outcomes and quality of life for patients across the United States.

Incyte Corporation invites organizations to submit membership requests aimed at enhancing healthcare access for patients and advocates. As a biopharmaceutical leader, Incyte supports initiatives that align with its mission to improve patient lives through grants and contributions. Eligible entities include medical schools, associations, non-profits, and advocacy groups. Requests should comply with Incyte's regulatory standards and be submitted at least 60 days prior to the required decision date.

Incyte Corporation, a biopharmaceutical leader, offers healthcare sponsorships to support organizations focused on improving patient care and access to healthcare information. Eligible applicants include medical schools, associations, non-profits, advocacy groups, and hospitals. Requests should align with Incyte's commitment to enhancing the lives of patients affected by cancer and other diseases, ensuring compliance with regulatory guidelines. Organizations must enter a written agreement with Incyte to receive funding.

The Cancer Center Improving Cancer Outcomes Pilot Funding, offered by the Indiana Clinical and Translational Sciences Institute (CTSI), aims to support innovative pilot projects that enhance cancer-related outcomes across the U.S. This program invites proposals focusing on populations with higher cancer burdens, emphasizing evidence-based strategies for prevention, detection, treatment, and survivorship. By fostering interdisciplinary collaboration, the initiative seeks to tackle real-world barriers and generate actionable solutions to improve community health.

The Patient-Centered Outcomes Research Institute (PCORI) is announcing funding for comparative clinical effectiveness research across the cancer care continuum. This initiative aims to empower researcher-community partnerships to tackle significant healthcare challenges faced by patients and caregivers in the U.S. The focus is on enhancing care delivery and outcomes by addressing barriers to screening, treatment, and follow-up care for cancer patients. Applications are encouraged to identify strategies that improve patient-centered outcomes.

The Pinetop Assistance League (PAL) Grant provides crucial financial support to elderly blues musicians, ensuring their well-being during emergencies. This grant, part of the Pinetop Perkins Foundation's mission, offers assistance for medical expenses, home care, and essential living costs. Eligible applicants must be professional artists aged 50 or older with a household income below $35,000. By addressing these needs, PAL plays a vital role in preserving the legacy and care of blues musicians.

This funding opportunity from the Patient-Centered Outcomes Research Institute aims to enhance health decision-making through comparative clinical effectiveness research, focusing on critical areas such as cancer, maternal health, and mental health. The initiative encourages robust observational studies that utilize existing data to derive patient-centered insights. Applications must address specific themes approved by PCORI and demonstrate potential benefits to the U.S. healthcare system, thus ensuring relevance and stakeholder engagement in research efforts.

The Alternatives in Research (AiR) Challenge program, initiated by the Alternatives Research & Development Foundation (ARDF), seeks innovative research proposals that focus specifically on childhood cancer. Projects must demonstrate the value of non-animal methodologies in biomedical research, emphasizing non-clinical or pre-clinical studies. Eligible applicants include non-profit, tax-exempt institutions in the US with qualified researchers. This program aims to improve knowledge and treatment of childhood cancers while adhering to ethical research standards.